Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab for Recurrent Uterine Serous Carcinoma
NCT05870761Phase 2Active, not recruiting
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in uterine serous carcinoma (USC). Primary endpoint: Overall Response Rate at 2 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT05870761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870761.